Skip to main content Accessibility help

Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease

  • James W. Tetrud


Levodopa has played a central role in the treatment of Parkinson's disease for nearly 40 years and remains the single most effective symptomatic treatment for the disease. However, the response to levodopa therapy changes over time, and its long-term use is commonly associated with disabling motor complications. For this reason, the appropriate role of levodopa in the treatment of Parkinson's disease—in particular, the question of when to initiate therapy with the drug—has been a matter of controversy. Because levodopa is the most effective treatment for Parkinson's disease, the management of this disease becomes a matter of balancing short-term symptom control with long-term functional outcomes. This article provides an overview of the basis for levodopa-associated motor complications and their impact on patients' clinical function and quality of life, followed by a discussion of strategies for managing these complications to achieve optimum symptom control while minimizing the adverse effects of long-term therapy.


Corresponding author

Please direct all correspondence to: James W. Tetrud, MD, The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089; Tel: 408-734-2800; E-mail:


Hide All
1. National Center for Health Statistics. NCHS data on Parkinson's disease. Available at: 2005. Accessed on July 19, 2006.
2.Tanner, CM, Aston, DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol. 2000;13:427430.
3.Lang, AE, Lozano, AM. Parkinson's disease. First of two parts. N Engl J Med. 1998;339:10441053.
4.Guttman, M, Kish, SJ, Furukawa, Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ. 2003;168:293301.
5.Braak, H, Del Tredici, K, Rub, U, de Vos, RA, Jansen Steur, EN, Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197211.
6.Colcher, A, Simuni, T. Clinical manifestations of Parkinson's disease. Med Clin North Am. 1999;83:327347.
7.Dhawan, V, Healy, DG, Pal, S, Chaudhuri, KR. Sleep-related problems of Parkinson's disease. Age Aging. 2006;35:220228.
8.Koller, WC, Tse, W. Unmet medical needs in Parkinson's disease. Neurology. 2004;62(suppl 1):S1S8.
9.Rascol, O, Goetz, C, Koller, W, Poewe, W, Sampaio, C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359:15891598.
10.Hoehn, MM, Yahr, MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427442.
11.Koller, W, Guarnieri, M, Hubble, J, Rabinowicz, AL, Silver, D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm. 2005;112:221230.
12.Cohen, G, Spina, MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989;26:689690.
13.Schapira, AH, Obeso, J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59:559562.
14.Aminoff, MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol. 2006;59:562564.
15.Fahn, S, Oakes, D, Shoulson, I, et al.Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:24982508.
16.Thanvi, BR, Lo, TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004;80:452458.
17.Adler, CH. Relevance of motor complications in Parkinson's disease. Neurology. 2002;58(suppl 1):S51S56.
18.Muller, T, Russ, H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother. 2006;7:17151730.
19.Sato, K, Hatano, T, Yamashiro, K, et al.Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21:13841395.
20.Schrag, A, Quinn, N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000;123(pt 11):22972305.
21.Mazzella, L, Yahr, MD, Marinelli, L, Huang, N, Moshier, E, Di Rocco, A. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy. Parkinsonism Relat Disord. 2005;11:151155.
22.Mccoll, CD, Reardon, KA, Shiff, M, Kempster, PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord. 2002;17:12271234.
23.Rajput, AH, Fenton, ME, Birdi, S, et al.Clinical-pathological study of levodopa complications. Mov Disord. 2002;17:289296.
24.Marsden, CD, Parkes, JD, Quinn, N. Fluctuations of disability in Parkinson's deseaseclinical aspects. In: Marsden, CD, Fahn, S, eds. Movement Disorders. Boston, Mass: Butterworth Scientific; 1982;96122.
25.Ahlskog, JE, Muenter, MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448458.
26.Blanchet, PJ, Allard, P, Gregoire, L, Tardif, F, Bedard, PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23:189193.
27.Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:19311938.
28.Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol. 1996;39:3745.
29.Stacy, M, Bowron, A, Guttman, M, et al.Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726733.
30.Nutt, JG, Woodward, WR, Carter, JH, Gancher, ST. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol. 1992;49:11231130.
31.Barbato, L, Stocchi, F, Monge, A, et al.The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol. 1997;20:394401.
32.Nutt, JG, Carter, JH, Lea, ES, Sexton, GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002;51:686693.
33.Obeso, JA, Rodriguez-Oroz, M, Marin, C, et al.The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62(suppl 1):S17S30.
34.Metman, LV, Konitsiotis, S, Chase, TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000;15:38.
35.Olanow, CW, Obeso, JA, Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677687.
36.Chapuis, S, Ouchchane, L, Metz, O, Gerbaud, L, Durif, F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005;20:224230.
37.Wilson, RE, Silver, D, Spears, JB, Van Lunen, BE. Implications of motor fluctuations in Parkinson's patients on chronic therapy (IMPACT) registry: quality of life (QOL) data. Mov Disord. 2006;21(suppl 1):S151.
38.Bloem, BR, Hausdorff, JM, Visser, JE, Giladi, N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord. 2004;19:871884.
39.Martinez-Martin, P, Benito-Leon, J, Alonso, F, et al.Quality of life of caregivers in Parkinson's disease. Qual Life Res. 2005;14:463472.
40.Witjas, T, Kaphan, E, Azulay, JP, et al.Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology. 2002;59:408413.
41.van Laar, T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs. 2003;17:475489.
42. Parcopa [package insert]. Milwaukee, Wis: Schwarz Pharma; 2006.
43. Sinemet [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
44. Sinemet CR [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
45. Stalevo [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2004.
46. Apokyn [package insert]. Research Triangle Park, NC: Mylan Bertek Pharmaceuticals, Inc.; 2004.
47. Parlodel Snap Tabs [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.
48. Permax [package insert]. Indianapolis, Ind: Eli Lilly & Co.; 2001.
49. Mirapex [package insert]. Ridgefield, Conn: Boehringer-Ingelheim International GmbH; 2006.
50. Requip [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
51. Comtan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2000.
52. Tasmar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.
53. Azilect [package insert]. Kansas City, Mo: Teva Pharmaceutical Industries, Ltd.; 2006.
54. Eldepryl [package insert]. Tampa, Fla: Somerset Pharmaceuticals; 1998.
55. Zelapar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.
56. Symadine [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.
57. Symmetrel [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; 2002.
58. Cogentin [package insert]. Whitehouse Station, NJ; Merck & Co., Inc.; 2006.
59. Artane [package insert]. Pearl River, NY: Lederle Pharmaceutical Division; 2003.
60.Grosset, KA, Bone, I, Grosset, DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20:15021507.
61.Koller, WC, Hutton, JT, Tolosa, E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53:10121019.
62.Olanow, CW, Watts, RL, Koller, WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):S1S88.
63.Lieberman, A, Ranhosky, A, Korts, D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162168.
64.LeWitt, PA, Chang, F-L, Fazzini, E, Nausieda, PA, Daniel, T, Boroojerdi, B. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson's disease. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 17-20, 2005; Athens, Greece.
65.Poewe, W, Giladi, N, Maguire, D, Boroojerdi B. Rotigotine transdermal patch in patients with parkinson's disease and motor fluctuations. 24H symptom control in a placebo- and Pramipexole-controlled, randomized, double-blind, double dummy trial. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.
66.Pahwa, R, Factor, SA, Elmer, LW. Ropinirole 24-hour prolonged release reduces ‘off’ time in patients with parkinson's disease not optimally controlled with L-Dopa. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.
67.Dodd, ML, Klos, KJ, Bower, JH, Geda, YE, Josephs, KA, Ahlskog, JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:13771381.
68.Watts, RL, Jankovic, J, Waters, C, Rajput, A, Boroojerdi, B, Rao, J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272276.
69.Avorn, J, Schneeweiss, S, Sudarsky, LR, et al.Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005;62:12421248.
70.Pezzella, FR, Colosimo, C, Vanacore, N, et al.Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005;20:7781.
71.Pontone, G, Williams, JR, Bassett, SS, Marsh, L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:12581261.
72.Sundberg, S, Scheinin, M, Illi, A, Akkila, J, Gordin, A, Keranen, T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol. 1993;36:451456.
73.Zanettini, R, Antonini, A, Gatto, G, Gentile, R, Tesei, S, Pezzoli, G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:3946.
74.Van Camp, G, Flamez, A, Cosyns, B, et al.Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:11791183.
75.Horvath, J, Fross, RD, Kleiner-Fisman, G, et al.Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656662.
76.Waters, CH, Sethi, KD, Hauser, RA, Molho, E, Bertoni, JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426432.
77.Stocchi, F. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract. 2006;60:215221.
78.Rascol, O, Brooks, DJ, Melamed, E, et al.Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947954
79.Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241248.
80.Goetz, CG, Poewe, W, Rascol, O, Sampaio, C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20:523539.
81.Thomas, A, lacono, D, Luciano, AL, Armellino, K, Di Iorio, A, Onofrj, M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75:141143.
82.Luginger, E, Wenning, GK, Bosch, S, Poewe, W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15:873878.
83.Weller, M, Kornhuber, J. Amantadine withdrawal and neuroleptic malignant syndrome. Neurology. 1993;43:2155.
84.Anticholinergic therapies in the treatment of Parkinson's disease. Mov Disord. 2002;17(suppl 4):S7S12.
85.Katzenschlager, R, Sampaio, C, Costa, J, Lees, A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;CD003735.
86.Stocchi, F, Olanow, CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology. 2004;62(suppl 1):S56S63.
87.Adler, CH, Singer, C, O'Brien, C, et al.Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55:10891095.
88.Borges, N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26:743747.
89.Hauser, RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology. 2004;62(suppl 1):S64S71.
90.Stocchi, F, Vacca, L, Grassini, P, et al.Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. Neurol Sci. 2003;24:217218.
91.Parkinson Study Group. Entacapone improves motor fluctuations in levodopatreated Parkinson's disease patients. Ann Neurol. 1997;42:747755.
92.Rinne, UK, Larsen, JP, Siden, A, Worm-Petersen, J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51:13091314.
93.Poewe, WH, Deuschl, G, Gordin, A, Kultalahti, E-R, Leinonen, M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245255.
94.Reichmann, H, Boas, J, Macmahon, D, Myllyla, V, Hakala, A, Reinikainen, K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111:2128.
95.Brooks, DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(suppl 1):S39S46.
96.Silver, DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rev Neurother. 2004;4:589599.
97.Brooks, DJ, Agid, Y, Eggert, K, Widner, H, Ostergaard, K, Holopainen, A; TC-INIT Study Group. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005;53:197202.
98.Myllyla, V, Haapaniemi, T, Kaakkola, S, et al.Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand. 2006;114:181186.
99.Dewey, RB Jr, Hutton, JT, LeWitt, PA, Factor, SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:13851392.
100.Zijlmans, JC, Debilly, B, Rascol, O, Lees, AJ, Durif, F. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord. 2004;19:10061011.
101.Pahwa, R, Factor, SA, Lyons, KE, et al.Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983985.

Related content

Powered by UNSILO

Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease

  • James W. Tetrud


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.